InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
0.970
+0.050 (5.42%)
At close: Mar 6, 2026, 4:00 PM EST
0.921
-0.049 (-5.05%)
After-hours: Mar 6, 2026, 5:30 PM EST
InflaRx Employees
InflaRx had 74 employees as of December 31, 2024. The number of employees increased by 12 or 18.97% compared to the previous year.
Employees
74
Change (1Y)
12
Growth (1Y)
18.97%
Revenue / Employee
$996
Profits / Employee
-$635,850
Market Cap
65.71M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| Mereo BioPharma Group | 36 |
| eXoZymes | 31 |
| AN2 Therapeutics | 22 |
| NeurAxis | 21 |
| Annovis Bio | 15 |
| MediciNova | 13 |
| Cingulate | 13 |
IFRX News
- 9 days ago - InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - InflaRx Announces Participation in February Investor Conferences - GlobeNewsWire
- 2 months ago - InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - GlobeNewsWire
- 2 months ago - InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - GlobeNewsWire
- 3 months ago - InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 - GlobeNewsWire
- 4 months ago - InflaRx N.V. (IFRX) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa Transcript - Seeking Alpha
- 4 months ago - InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) - GlobeNewsWire
- 4 months ago - InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria - GlobeNewsWire